# Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients

> **NCT06203704** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1086 (actual)

## Conditions studied

- Chronic Kidney Disease (CKD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06203704
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-20
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 1086 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06203704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06203704, "Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06203704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*